Sex Differences in 6-Mercaptopurine Use in Childhood Leukaemia
Author Information
Author(s): J.S. Lilleyman, L. Lennard, C.A. Rees, G. Morgan, J.L. Maddocks
Primary Institution: The Children's Hospital, Sheffield
Hypothesis
Do boys and girls respond differently to 6-mercaptopurine treatment in childhood lymphoblastic leukaemia?
Conclusion
Girls develop 6-mercaptopurine cytotoxicity at lower doses and more predictably than boys.
Supporting Evidence
- Girls showed a significant correlation between 6MP dose and 6TGN concentration, while boys did not.
- Boys tolerated higher doses of 6MP but did not show increased cytotoxicity.
- The study involved 79 assays of 6TGN concentrations over 11 months.
Takeaway
Boys and girls with leukaemia react differently to a medicine called 6-mercaptopurine, with girls needing less of it to get the same effect.
Methodology
The study measured red cell 6-thioguanine nucleotide concentrations in children on a standard treatment regimen for leukaemia.
Potential Biases
Potential bias due to the small sample size and the specific treatment regimen used.
Limitations
The sample size was small and may not represent the broader population.
Participant Demographics
22 children aged 3-13 years, including 12 boys and 10 girls.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website